BBS-Bioactive Bone Substitutes’ patent application, “A Method for Preparing a Bone Protein Preparation and a Bone Protein Preparation,” has been accepted in the U.S. The company’s ARTEBONE® product is now patented in the U.S., Canada and European and Eurasian regions. A patent application regarding production is still in progress in the U.S.
ARTEBONE comprises a ready-to-use mineral scaffold and bone proteins that promote bone growth in the extremities, scapula and pelvis. It is used primarily for the treatment of bone defects and healing problems in extremities such as foot and ankle. In the future, ARTEBONE can be expanded for other indication areas including tibia and spine. The company expects to receive approval under the CE Mark and launch in Europe within 12 months.
CEO Ilkka Kangasniemi said, ”The USA is the most significant market of orthopaedic products. Thus, this news about the patent approval is very remarkable for our company. Now the ARTEBONE product and its unique component, bone protein extract, are protected by patents around all major market areas globally.”
BBS-Bioactive Bone Substitutes' patent application, "A Method for Preparing a Bone Protein Preparation and a Bone Protein Preparation," has been accepted in the U.S. The company’s ARTEBONE® product is now patented in the U.S., Canada and European and Eurasian regions. A patent application regarding production is still in progress in the U.S. ...
BBS-Bioactive Bone Substitutes’ patent application, “A Method for Preparing a Bone Protein Preparation and a Bone Protein Preparation,” has been accepted in the U.S. The company’s ARTEBONE® product is now patented in the U.S., Canada and European and Eurasian regions. A patent application regarding production is still in progress in the U.S.
ARTEBONE comprises a ready-to-use mineral scaffold and bone proteins that promote bone growth in the extremities, scapula and pelvis. It is used primarily for the treatment of bone defects and healing problems in extremities such as foot and ankle. In the future, ARTEBONE can be expanded for other indication areas including tibia and spine. The company expects to receive approval under the CE Mark and launch in Europe within 12 months.
CEO Ilkka Kangasniemi said, ”The USA is the most significant market of orthopaedic products. Thus, this news about the patent approval is very remarkable for our company. Now the ARTEBONE product and its unique component, bone protein extract, are protected by patents around all major market areas globally.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
